Mon, Jul 14, 2014, 1:20 AM EDT - U.S. Markets open in 8 hrs 10 mins


% | $
Quotes you view appear here for quick access.

Galena Biopharma, Inc. Message Board

  • jim.beemer Oct 7, 2013 9:20 AM Flag

    News This Morning Is MASSIVE!!!

    GALE should be trading at $5 on this news. Below is the release from Briefing. This essentially destroys the short argument. It explains "WHY" NeuVax works in those with low to intermediate levels of HER2. This question was first raised by Adam F, but biomarkers hold the answer. NeuVax works and bears are going to have a tough time arguing this news.Can't wait for conference

    A number of variables were analyzed, including HER2 levels, effect of boosters, induction, and amplification of the NeuVax T-cell response. The data demonstrates that induction, rather than amplification, of an anti-HER2 immune response confers optimal clinical benefit and may partially explain why NeuVax works in HER2 IHC 1+/2+ patients with low-to-intermediate HER2 antigen exposure. This data is consistent with previously published biomarker data indicating a correlation between increasing NeuVax specific T-cells following vaccination and reductions in breast cancer recurrence rates.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.85+0.04(+1.42%)Jul 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.